Large and small plaque variants of A12 foot-and-mouth disease virus were shown to have specific antigenic determinants. Large plaque virus antigenic specificity was destroyed by trypsin treatment, but the small plaque antigen was resistant despite cleavage of the trypsin-sensitive polypeptide. The cleavage of polypeptide VPa by trypsin resulted in the formation of a new antigen not present on untreated virus. The effects of chymotrypsin and trypsin on the polypeptides of the plaque variants have been examined and related to changes in antigenicity, infectivity, and exposure of the polypeptides at the surface of the capsid. The results are discussed in relation to the orientation of the trypsin-sensitive polypeptide in the virus capsid.
INTRODUCTION
The large plaque (LP) and small plaque (SP) variants of several serotypes of foot-andmouth disease virus (FMDV) have different antigenic characteristics (Cowan, I969; McVicar & Sutmoller, I972a; Cowan et al. I974) . Virus passed on monolayer or suspension cultures of baby hamster kidney (BHK)-21 cells selectively produced LP and SP variants, respectively (Cowan et al. I974) . In similar experiments, Meloen 0976) reported that O1 FMDV grown in BHK suspension cultures and virus produced in the Frenkel culture system of bovine tongue epithelium differed antigenically. Trypsin-treated virus from Frenkel culture (Frenkel, I95o) lost its specific antigenicity and appeared identical on immunodiffusion to the suspension culture virus. This finding, coupled with information that trypsin removes a site on the virion associated with immunogenicity (Brown & Smale, 197o) , led to the conclusion that the suspension cell virus was antigenically deficient and had lost the trypsin-sensitive site. However, Cowan et al. (1978) have shown that both LP and SP viruses have unique antigenic properties associated with the trypsin-sensitive site on the virion. This indicated that SP virus was not deficient antigenically but was different from LP virus.
Results in the present report confirm the distinct antigenic properties of LP and SP variants using A12 FMDV. The presence of the trypsin-sensitive virus polypeptide is shown for each variant. In addition, differences in polypeptide cleavage with enzyme treatment are shown and related to changes in antigenicity and infectivity. 
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Freund's adjuvant (Cowan, 1968) . The same variant recognition capability shown in Results was obtained with antisera prepared by both methods. Guinea pig hyperimmune virus antiserum was produced as previously described (Cowan, 1969) . Chymotrypsin-and trypsintreated viruses in incomplete Freund's adjuvant were inoculated subcutaneously in z5/~g doses and antisera collected at 3o days post-inoculation (Cowan, ~969) . Antisera to the enzyme-treated viruses were absorbed at slight antigen excess with untreated virus to remove virus-reactive antibody. The approximate equivalence point was determined by immunodiffusion analysis of supernatant fluids in a test absorption series for unreacted virus or antibody (Sutmoller & Cowan, I974) . ImmunodigCusion analysis. Ouchterlony type immunodiffusion tests were performed in I ~o agar (Cowan & Graves, I966 ) , with an additional o'15 M-NaC1 added to the agar (Cowan et al. I974) .
Polyacrylamide gel electrophoresis. The polypeptides of the AI~ FMDV sample were resolved on I2. 5 % polyacrylamide gels containing o.1% sodium dodecyl sulphate (SDS) and 8 M-urea (Bachrach et al. 1975) ; 9 cm long, 1"z7 mm thick slab gels were used rather than cylindrical gels (except Fig. 4b ). The gels were fixed in 50% trichloroacetic acid for I h and washed in z5% propanol and Io% acetic acid before they were stained with Coomassie brilliant blue. This method caused the trypsin-sensitive polypeptide to migrate as VP3 rather than as VP2 as in an earlier method (Vande Woude et al. 1972) or elsewhere as VP1 (Wild et al. 1969) . To avoid confusion, in this report the trypsin-sensitive polypeptide is referred to as VPa. Mol. wt. of virus polypeptide VP3 and fragments of VP~ produced by enzyme cleavage were determined by comparison with marker proteins (bovine serum albumin, IgG heavy chain, aldolase, chymotrypsinogen, pancreatic ribonuclease, cytochrome c) on gel slabs as above, with the exception that they contained t5 % acrylamide and only o'5 M-urea. The tool. wt. values are presented in the Results in abbreviated form (e.g. pi4"9 for tool. wt. I4 9oo). Mol. wt. values assigned to the peptide fragments are relative considering the method used. However, the differences were certain and reproducible from the side-by-side analyses on slab gels. Thus, the values are given in the Results to illustrate these differences.
The relative recovery of the weight of VP~ in enzyme-cleaved products of VPa was also determined by counting the radioactivity recovered in the various peptides of 14C-amino acid labelled FMDV. Cylindrical 0.6 cm diam. gels containing I t % polyacrylamide, o.I % SDS and 8 M-urea were electrophoresed, divided into I mm fractions and radioactivity was determined by liquid scintillation counting.
Labelling of virus particles with ~2 ~I. The general method of Hunter & Greenwood (1962) was used to label 5 ° #g of virus with I oo #Ci of Na125I by addition of I o #g of chloramine-T. After I min, the reaction was stopped with sodium metabisulphite, and excess KI and bovine serum albumin were added. Before the a25I-labelled samples were electrophoresed on slab gels, intact labelled virus was re-purified (as with trypsin-treated purified virus above) to eliminate soluble l~aI and virus material possibly degraded during labelling. Labelled virus samples were run on SDS-polyacrylamide gels containing 8 M-urea and to % acrylamide, the gels were then fixed and washed, dried onto filter paper at 8o °C under vacuum and applied to X-ray film to locate the labelled virus polypeptides. 
RESULTS

Effect of enzyme treatment on virus antigenicity
The LP and SP isolates ofAl~ FMDV were compared by immunodiffusion with 7-day p.i. sera prepared to each of the viruses. Each antiserum precipitated the two isolates, but a specific spur line that formed over the heterologous isolate showed that each carried a characteristic LP or SP antigenic determinant (Fig. Ia) . When trypsin-treated isolates were compared (LP antiserum), the trypsinized large plaque (T-LP) virus had lost the specific antigenicity, and the precipitin line coalesced with the trypsinized small plaque (T-SP) virus (Fig. I b) . However, the SP-specific antigenicity (SP antiserum) remained despite trypsin treatment, even with a higher concentration of TPCK-trypsin (245 units/ml) or with I o units/ml of trypsin not treated with the chymotrypsin inhibitor T P C K (Fig. I c) . The trypsin resistance of SP-soecific antigenicity was also apparent when T-SP was corn- The difference in sensitivity of the specific antigens of LP and SP viruses to trypsin was confirmed with the LP b-antigenic variant of AI~ FMDV and additional recently isolated LP and SP stocks from A12 FMDV (see Methods). In each experiment the LP-specific antigen was lost and the SP antigen remained after trypsin treatment (not shown).
Treatment of both LP and SP isolates with chymotrypsin had no detectable effect on their specific antigenicity (Fig. I d) and extended treatment (Io units/ml, I h) did not reduce the degree of specific spurring of either isolate.
The difference in sensitivity of the LP and SP virus-specific antigens to enzyme treatment was supported by a comparison of LP and SP virus with each of their respective trypsin and chymotrypsin products (Fig. 2) . Consistent with the loss of specific antigenicity with trypsin, LP virus produced a strong spur-line over T-LP virus indicating a considerable loss or change in antigenicity (Fig. 2a) . Chymotrypsin treatment altered the antigenicity less with only a slight spur showing from the LP precipitin line. More extensively treated LP virus allowed a larger spur to form, but both chymotrypsin-treated LP preparations maintained a strong spur line over T-LP virus comparable to the LP-T-LP spur. Trypsin and chymotrypsin treatment of SP virus had little effect on its antigenic reactivity (Fig. 2 b) . A precipitin line of identity formed with untreated and treated SP virus; only a faint spur-line showed from the SP virus over the treated samples. Thus, the stability of the SP-specific antigen after enzyme treatment was reflected by a lack of loss (or change) in antigenicity shown here.
The loss of LP antigenicity shown above supports previous findings that trypsin removes an antigenic site on the virus particle (Wild et al. I969). Multiple antigenic sites were shown on the virus particle, including one that was present after trypsin treatment and distinct from the antigen removed by trypsin (Brown & Smale, 197o; Rowlands et al. I97I) . However, these studies did not show whether the antigen was newly formed and specific for trypsinized virus or shared on untreated virus particles. To test this, antiserum prepared with trypsinized A12 F M D V was compared with hyperimmune and 7-day p.i. LP antiserum by immunodiffusion with LP and T-LP virus (Fig. 3a) . Hyperimmune serum did not distinguish between the two viruses and the 7-day p.i. serum showed a loss of antigenicity seen above with T-LP virus (Fig. za) . Antiserum to trypsinized virus reacted like hyperimmune serum with the exception that a spur-line formed from T-LP over the LP virus precipitin line. When trypsin-virus antiserum was absorbed with untreated virus, reactivity remained which was specific for trypsin-treated virus. Thus, although trypsin-treated virus induced antibody reactive with intact virus, it also induced antibody activity specific for an antigen on trypsinized virus alone. Enzyme-treated LP and SP viruses were each examined for the appearance of the trypsinspecific antigen. Both T-LP and T-SP viruses produced a trypsin-specific spur line over untreated virus, and trypsin virus-specific antiserum (intact virus absorbed) precipitated only T-LP and T-SP virus (Fig. 3b, c) . The lack of reaction with chymotrypsin-treated LP or SP virus indicated that the trypsin-specific antigen was not induced by this enzyme. Also, chymotrypsin-treated virus did not acquire a 'chymotrypsin-specific' virus antigen. Antiserum prepared to chymotrypsin-treated virus showed a coalescing precipitin line with LP or SP virus and their respective enzyme-treated products (for example, LP virus, Fig. 3 d) . When absorbed with untreated virus, the antiserum lost reactivity with all LP virus preparations. The experiments above indicated that the persistence of SP-specific antigenicity was not due to a lack of trypsin effect on the capsid, for both LP and SP virus showed the appearance of the trypsin-specific antigen.
Effect of enzyme treatment on the polypeptides of LP and SP virus
Treatment of LP virus with Io units/ml of trypsin or TPCK-trypsin completely cleaved VP 3 (approx. p25) to smaller fragments that were retained in the virus particle (Fig. 4a) . The sizes of the fragments were different with the two enzyme preparations: pi4. 9 for TPCK-trypsin and pi4. 5 (trace pi6.8) for untreated trypsin. TPCK-trypsin cleavage of VP3 was complete, and the size of the fragment the same whether at a previously used lower dose of about I unit/ml (Bachrach et al. I975) or of 245 units/ml (not shown). The cleavage product was seen as a single band and not as a closely spaced pair as previously reported (Bachrach et al. I975) . However, in most tests, the staining intensity of the cleaved VP3 product indicated that the original amount of VP3 protein was present (Fig. 4b) . Tests for l~C-activity in trypsin cleaved VP3 indicated that 77 % of the original VP3 was recovered as P~4"9-Trypsinization of 14C-virus also produced a quantity of radioactivity smaller than VP~ which, if all derived from VP3, represented 2o % of VPa.
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(a) Treatment of LP virus with chymotrypsin (5 units/ml, 15 min) produced a fragment, larger than the trypsin products, of Pt5"4 and a smaller amount of Pt4"5, equivalent to the trypsin (not TPCK-treated) product (Fig. 4a, c) . Some VP3 remained uncleaved. More extensive chymotrypsin treatment (~o units/ml, I 11) cleaved VP~ completely and produced mostly the smaller fragment pi4"5 and some pi5"4 (Fig. 4e) .
Enzyme treatments of the SP isolate produced an array of mol. wt. fragments of VP3 similar to that seen with LP virus (Fig. 5a ). However, before enzyme treatments, most samples of purified SP virus showed partial cleavage of VP3 to a pr5"o fragment. Virus produced in BHK-zt cells from another source or in primary calf kidney cultures contained the fragment. The VP3 appeared to cleave during incubation in the culture fluid, as early harvests or virus collected from the cell cytoplasm yielded virus with most VP3 intact and little cleavage product. On standing at 4 °C, purified samples of SP virus lost additional VPs to the p~5"o fragment. The LP isolate appeared to be more stable; little cleavage product ever appeared on storage at 4 °C.
Treatment of the SP isolate with chymotrypsin increased the amount of pI5"o fragment already present in untreated SP virus. Also, some intact VP3 remained (Fig. 5 a, b) and traces of P~4"3 and pi9"o fragments were formed. As with LP virus, more extensive chymotrypsin treatment (Io units/ml, I h) cleaved the balance of VP3 (Fig. 5b ). Unlike LP virus which then contained principally the smallest species, about equal parts of the three SP cleavage products were formed.
Trypsin treatment of SP virus caused complete cleavage of VPa to a fragment pi4.6 with TPCK-trypsin and to pi4"3 (plus trace P~7"4) with trypsin (Fig. 5 a) . Treatment of SP virus in which most of the VP3 had spontaneously degraded to pi5"o yielded either pi4"6 or p t4"3 according to the type of trypsin used. Insufficient intact VP3 was originally present to account for the amount of trypsin-cleaved products found. Therefore, the pI5"o fragment found in untreated virus must have been retained in the capsid and cleaved further, along with the intact VPa, to form the smaller products. The smaller VP3 fragment produced by trypsin versus TPCK-trypsin appeared to result from additional contaminating chymotrypsin activity. A mixture of Io units/ml TPCK-trypsin plus 5 units/ml of chymotrypsin produced the pi4"3 and P~7"4 fragments typical of untreated trypsin except that more of the larger species was generated (Fig. 5 e) . The enzyme treatments described above produced different cleavage products of VPa. However, the enzyme effects were specific for VPa. Polypeptides VP1, VP2 and VPo, VP4 (both not apparent in the figures) were not altered in mobility by any of the enzyme treatments.
Infectivity of enzyme-treated LP and SP virus
Infectivity of LP and SP virus was significantly reduced by trypsin treatment. When LP virus was treated with Io units/ml of trypsin or TPCK-trypsin, infectivity dramatically decreased in the first 5 min of incubation and changed little after that (Fig. 6a) . The SP virus showed a similar loss of infectivity complete by 5 min, but less infectivity was lost with TPCK-trypsin (Fig. 6b) . This difference between LP and SP virus was more apparent when I unit/ml of TPCK-trypsin was used. As shown by polyacrylamide gel electrophoresis, this dose of TPCK-trypsin was sufficient to completely cleave VP3 in preparations of purified virus containing much larger amounts of virus protein (Bachrach et aL t975) .
Chymotrypsin had little effect on infectivity of either LP or SP virus in the first I5 min of incubation (Fig. 6) . However, by I h, LP virus infectivity loss was extensive. The time of the infectivity loss coincided with the conversion of the pI 5"4 fragment and residual VP3 to the smaller pI4. 5 fragment (Fig. 4e) . The SP virus infectivity was less affected through the I h incubation period. This difference probably reflects the limited conversion of the pI5"o fragment to the smaller pI4"3 fragment seen with prolonged chymotrypsin treatment (Fig. 5b) . The maintenance of infectivity in SP virus particles containing VPs as pt5"o was supported by the finding that some untreated SP virus samples contained this fragment and little intact VP3. However, these preparations had high infectivity titres comparable to those of other preparations containing virus with intact VP3.
Labelling of polypeptides in enzyme-treated viruses
Treatment of the LP and SP isolates of AlZ FMDV with trypsin, chymotrypsin or a mixture of the two cleaved only VPs. Also, when intact FMD viruses were labelled in vitro with 125I, the trypsin-sensitive peptide (here VP3) accumulated most of the label (LaPorte & Lenoir, I973; Bachrach et al. I975). To determine whether VPs cleavage caused the other polypeptides to become exposed at the surface of the capsid, enzyme-treated virus particles were tested for incorporation of 125I into tyrosine of the virus polypeptides (Fig. 7) . Although all of the polypeptides became labelled when solubilized in 8 M-urea, VP3 was principally labelled in situ in intact particles. With enzyme-treated particles, the cleaved VPs fragments became labelled. In untreated viruses, polypeptide VP2 showed a small amount and VP1 a trace (not visible in Fig. 7 ) uptake of 125I. Uptake of 125I did not increase in VP~ and VP2 with enzyme-treated particles. This finding indicated that tyrosine residues of these polypeptides did not become surface orientated.
DISCUSSION
The results presented here with A12 FMDV support previous findings for Asia-I and O1 FMDV that, in addition to common antigenic determinants, LP and SP isolates of FMDV show specific antigenic differences (McVicar & Sutmoller, I972a; Cowan et al. I974, I978) . The concept of an antigenic deficiency in the trypsin-sensitive polypeptide introduced by Meloen (I976) seems inaccurate. The virus grown in BHK suspension culture was thought to have 'lost' the trypsin-sensitive antigen. An immunodiffusion reaction of identity was found~for suspension culture virus and trypsin-treated Frenkel culture virus, the Frenkel virus known to have lost an immunogenic site (Brown & Smale, I97o) . However, when antisera to LP and SP variants were used to compare the variants, each was shown to contain antigenically different trypsin-sensitive determinants (Cowan et al. 1978) . The results presented here indicate that LP and SP variants of A12 FMDV contain the trypsin-sensitive polypeptide (here VPa) and also that the SP variant has its own specific antigenicity, different from that of LP virus.
The resistance of SP virus-specific antigenicity and smaller loss of infectivity with trypsin treatment differ from most reported results. Generally, effects of trypsin on FMDV were consistent and showed cleavage in one polypeptide and an associated loss of infectivity, antigenicity, immunogenicity and ability to absorb to cell receptors (Wild & Brown, I967; Strobbe et al. I974; Cavanagh et al. I977) . Specific LP and SP antigens of Asia-i and O1 FMDV were lost with trypsin treatment (Cowan et al. 1978) and for O1 FMDV (Frenkel) specificity was similarly lost (Meloen, I976). In the present tests, specific antigenicity of SP virus was not destroyed, despite the complete cleavage of VPa by trypsin. Additional examples of resistance of FMDV to trypsin have been reported. Trypsinized A12 (Bachrach et al. I975) and C~ (Rowlands et al. I97 I) FMDV produced about as much virus-neutralizing antibody in guinea pigs as untreated virus. Purified Ca FMDV infectivity was also resistant to trypsin despite polypeptide cleavage (Rowlands et al. 197I; H. L. Bachrach, personal communication) . These results indicate that other FMDV serotypes and strains may vary in their susceptibility to trypsin treatment.
In contrast to the trypsin effect, the specific SP and LP antigenicities were stable to chymotrypsin treatment. Also, no specific chymotrypsin-induced antigen was found comparable to the trypsin-specific antigen. With prolonged treatment, chymotrypsin caused further VPa cleavage to a smaller mol. wt. fragment. The conversion to the smaller polypeptide was more complete with LP virus and was reflected in a greater infectivity loss. These results agree with those of Cavanagh et al. (I977) in which a shift from tool. wt. 2ooo0 to 18o00 during chymotrypsin treatment was associated with loss of infectivity, cell absorption and, to a lesser degree, immunogenicity.
The principal enzyme cleavage products of A12 FMDV (mol. wt. I4ooo to I5ooo) found in the present study (also Bachrach et al. I975) differ from the fragments with tool. wt. 18ooo to aoooo plus < 1oo0o found for O1 FMDV (Strobbe et aL I974; Cavanagh et al. I977) . The difference probably reflects locations of susceptible peptide bonds exposed on the capsid surface of the two serotypes. The present results do not establish whether the single band seen with trypsin cleavage of VPa represented two polypeptides migrating together or a single species. The a5ooo mol. wt. assigned VPa in the present study is lower than tool. wt. 27 ooo to 3oooo determined by SDS-gel electrophoresis (Vande Woude et al. I972) and C-terminal analysis (Bachrach et al. I973)-Two co-migrating fragments of tool. wt. 15000 would appear to exceed the size of the parent VPa polypeptide. However, a recovery of 77 % of the original 14C-labelled VPz would set a single trypsin fragment at approx. 19 ooo to 23 ooo, a size not supported by comparison with standard protein markers. The difference may arise from a limited elution and degradation of VP3 fragments from an equal-sized pair in the virus capsid.
The presence of the mol. wt. 15 ooo polypeptide fragment in untreated SP virus did not affect its infectivity or antigenicity. In fact, large amounts of this fragment that formed spontaneously or with chymotrypsin treatment caused no significant changes in properties.
The tendency to form cleavage products does not mean the SP virus was deficient in VPa, but that it may have contained a principal chymotrypsin-specific site more exposed than on LP virus.
In this report, VP3 was cleaved by chymotrypsin, trypsin or a mixture to principally three different size classes of polypeptide fragments. Changes or lack of changes in infectivity and antigenicity were associated with the different products. The difference in mol. wt. of the largest and smallest fragments was less than mol. wt. Iooo for both variants. Although this difference in size could represent an antigenic determinant, physical loss of an antigenic segment seems unlikely to account for the change in properties. Rather, the variants could differ in the stability of configuration of cleaved VP3 in the capsid. This hypothesis is supported by the finding here that the pattern of VP3 cleavage by trypsin and crude trypsin was alike with SP and LP virus but that the associated antigenic changes differed. Also, VP 3 fragments obtained from trypsin-treated virus did not induce the formation of virusneutralizing antibody seen with intact VP3 (Bachrach et al. I975) . However, the same fragments contained in trypsin-treated virus capsids produced a neutralizing antibody response. Such conformational differences could account for the discrepancy in immunogenicity between trypsin-treated A12 FMDV (Bachrach et al. The importance of determining the properties of LP and SP variants of FMDV lies in their relationship to particular viruses causing foot-and-mouth disease in the field. Although properties and effects of enzymes on various serotypes of FMDV might be expected to vary, in this work, differences were shown for variants of the same serotype and subtype. In addition, antigenically different LP and SP variants were selectively produced on monolayer and suspension cell culture systems (Cowan et al. ~974; Meloen, ~976) . Different cell line susceptibility (Cowan et al. I974) , pathogenicity, and tissue localization (McVicar & Sutmoller, 1972b) have been noted for variants of FMDV. Finally, and most important, the immune responses (Meloen, I976) and protection in cattle to challenge with virulent FMDV (Cowan et al. ~974 ) differed with vaccines prepared with the virus variants. The differences listed above indicate the importance in understanding both the virus characteristics and cell system to be used in preparing effective vaccines for use in the field.
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